Recruiting

Whole Brain Radiation Therapy

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT05011045

Conditions

Central Nervous System Lymphoma

Hematopoietic and Lymphoid Cell Neoplasm

Leukemia

Lymphoma

Plasma Cell Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Magnetic Resonance Imaging

Neurocognitive Assessment

Quality-of-Life Assessment

Questionnaire Administration

Study Details

Brief summary:

This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.

Conditions

Central Nervous System Lymphoma

Hematopoietic and Lymphoid Cell Neoplasm

Leukemia

Lymphoma

Plasma Cell Myeloma

Study ID

NCT05011045

Start date

Jan 9, 2020

Status verified date

May, 2026

Completion date

Oct 31, 2026

Anticipated

Primary completion date

Oct 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age 18 years or older
  • Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma \[PCNSL\], secondary central nervous system lymphoma \[SCNSL\], leukemia, myeloma)
  • Proficient and capable of completing tests in English
  • Patients with claustrophobia are eligible if the claustrophobia is managed with medication
  • Patients with cognitively-impairment are eligible if the impairment is managed with medication
  • Patients who are pregnant

Study Design

Enrollment

100 participants

Anticipated

Interventions and Outcome Measures

Arms

Observational (neurocognitive assessment, questionnaires, MRI)

Patients undergo neurocognitive function assessments, complete questionnaires over 8-10 minutes and undergo standard of care MRI at baseline (within 4 weeks before the first day of WBRT), 2, 6, 12 months after RT completion, then annually for 5 years.

Interventions

Magnetic Resonance Imaging

Undergo MRI

Neurocognitive Assessment

Undergo neurocognitive function assessment

Quality-of-Life Assessment

Complete questionnaires

Questionnaire Administration

Complete questionnaires

Primary outcome measure

  • Cognitive outcomes [ Time Frame: Up to 5 years ]

Central Contacts and Locations

Central contacts

Dustin M Silk

713-563-3090dmdmsilk@mdanderson.orgsilk@mdanderson.org

Locations

M D Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Dustin M. Silk

713-563-3090dmsilk@mdanderson.org

Principal Investigator:

Bouthaina S. Dabaja

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

May 20, 2026

Last verified

May, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-05-20.